Education
About Us
Working with TipRanks
Follow Us
VHT - ETF AI Analysis
Top Page
Vanguard Health Care ETF (VHT)
Rating:72Outperform
Price Target:―
Positive Factors
Low Expense Ratio
The fund charges a very low fee, which helps investors keep more of their returns over time.
Large Asset Base
The ETF manages a sizable pool of assets, which can support liquidity and trading ease for investors.
Strong Core Health Care Holdings
Several major positions like Johnson & Johnson, Merck, Thermo Fisher, and others have shown solid gains, helping support the fund’s recent performance.
Negative Factors
Heavy Sector Concentration
With the vast majority of assets in health care, the fund is highly exposed to swings in that single sector.
High U.S. Market Exposure
Most of the portfolio is invested in U.S. companies, offering limited diversification across global markets.
Mixed Performance Among Top Holdings
Some large positions, such as AbbVie, Abbott Laboratories, and Intuitive Surgical, have shown weaker recent performance, which can drag on overall returns.
VHT vs. SPDR S&P 500 ETF (SPY)
AUM17.32B
RegionNorth America
Expense Ratio0.09%
Beta0.55
IssuerVanguard
Inception DateJan 26, 2004
Dividend Yield1.65%
Asset ClassEquity
Index TrackedMSCI US IMI 25/50 Health Care
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume250,137
30 Day Avg. Volume260,408
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
345.93Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering408
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VHT Summary
Vanguard Health Care ETF (VHT) is a fund that follows the MSCI US IMI 25/50 Health Care Index, giving you broad exposure to U.S. health care companies. It holds many types of businesses, including drug makers, biotech firms, medical device companies, and health insurers. Well-known holdings include Johnson & Johnson and UnitedHealth. Someone might invest in VHT to tap into long-term health care growth driven by aging populations and rising medical spending, while spreading risk across many companies. A key risk is that it is heavily focused on the health care sector, so it can rise or fall with that industry.
How much will it cost me?The Vanguard Health Care ETF (VHT) has an expense ratio of 0.09%, which means you’ll pay $0.90 per year for every $1,000 invested. This is lower than average because it is a passively managed fund that tracks an index, keeping costs low for investors.
What would affect this ETF?The Vanguard Health Care ETF (VHT) could benefit from long-term trends like aging populations, increased global health care spending, and advancements in medical technology, which drive demand for pharmaceuticals, biotechnology, and medical devices. However, it may face challenges from regulatory changes, patent expirations for major drug companies, or economic downturns that could impact health care budgets and innovation funding. Its focus on U.S.-based health care companies means it is particularly sensitive to domestic policy shifts and market conditions.
VHT Top 10 Holdings
VHT is a pure U.S. health care play, and its story right now is one of big drugmakers setting the tone. Johnson & Johnson, Merck, Amgen, and Gilead are all rising, giving the fund a solid backbone of steady pharma growth. On the flip side, heavyweight Eli Lilly has been losing steam lately, and health care services giant UnitedHealth, along with tools leader Thermo Fisher and Intuitive Surgical, are dragging on returns. Overall, performance is being driven more by classic Big Pharma than by devices or insurers.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 12.70% | $2.52B | $934.24B | 13.89% | 72 Outperform | |
| Johnson & Johnson | 8.22% | $1.63B | $579.34B | 44.22% | 78 Outperform | |
| AbbVie | 6.00% | $1.19B | $406.87B | 7.38% | 66 Neutral | |
| Merck & Company | 4.19% | $831.72M | $286.28B | 22.33% | 80 Outperform | |
| UnitedHealth | 3.96% | $784.71M | $260.03B | -41.95% | 72 Outperform | |
| Thermo Fisher | 3.33% | $659.77M | $186.47B | -5.59% | 72 Outperform | |
| Abbott Laboratories | 2.90% | $574.45M | $190.38B | -20.11% | 73 Outperform | |
| Amgen | 2.80% | $555.79M | $199.20B | 13.75% | 77 Outperform | |
| Intuitive Surgical | 2.75% | $545.83M | $174.07B | -5.42% | 78 Outperform | |
| Gilead Sciences | 2.68% | $531.87M | $178.68B | 22.59% | 78 Outperform |
VHT Technical Analysis
Negative
―
Price Trends
290.34
Negative
284.43
Negative
266.33
Positive
Market Momentum
-0.64
Positive
36.52
Neutral
26.56
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VHT, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 290.00, equal to the 50-day MA of 290.34, and equal to the 200-day MA of 266.33, indicating a neutral trend. The MACD of -0.64 indicates Positive momentum. The RSI at 36.52 is Neutral, neither overbought nor oversold. The STOCH value of 26.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VHT.
VHT Peer Comparison
Comparison Results
Performance Comparison
VHT
Vanguard Health Care ETF
282.15
18.51
7.02%
VGT
Vanguard Information Technology ETF
―
―
―
XLK
Technology Select Sector SPDR Fund
―
―
―
XLF
Financial Select Sector SPDR Fund
―
―
―
XLV
Health Care Select Sector SPDR Fund
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents